Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the $H^+/K^+$-ATPase enzyme system at the secretory surface of the gastric parietal cell.
## Primary Indications
* Erosive esophagitis associated with GERD.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Maintenance of healing of erosive esophagitis.
* Short-term treatment of GERD (off-label usage for stress ulcer prophylaxis in ICU settings).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg orally twice daily. Doses up to 240 mg/day have been utilized; titrate based on clinical response.
* **IV Bolus:** 40 mg given over 15 minutes.
## Pediatric Dosing
* **GERD (5 years and older):**
* 15 kg to <40 kg: 20 mg once daily.
* ≥40 kg: 40 mg once daily.
* *Note:* Safety and efficacy in children <5 years are not established for erosive esophagitis.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** Reduce frequency in severe hepatic impairment (Child-Pugh C); do not exceed 40 mg every other day or 20 mg daily.
## Contraindications
* Known hypersensitivity to pantoprazole or other substituted benzimidazoles (e.g., omeprazole).
* Concurrent use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, and increased risk of bone fractures (long-term, high-dose).
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of drugs like atazanavir, ketoconazole, and mycophenolate mofetil.
* **Methotrexate:** Potential increase in serum methotrexate levels (especially in high-dose therapy).
* **Warfarin:** Increased INR/prothrombin time; monitor closely when initiating or adjusting PPIs.
## Monitoring
* Monitor for signs of hypomagnesemia (e.g., tremors, arrhythmias) during long-term therapy.
* Evaluate for potential vitamin B12 deficiency in patients on chronic therapy (>1 year).
* Assess need for continued PPI therapy periodically; avoid unnecessary long-term use.
## Clinical Pearls
* **Administration:** Oral delayed-release tablets should be swallowed whole; do not chew or crush.
* **IV Stability:** IV preparation requires careful adherence to manufacturer instructions for reconstitution and dilution.
* **Transitioning:** Convert from IV to oral as soon as the patient can tolerate oral medications.
* **Uncertainty:** Dosing for specific critical care protocols (e.g., stress ulcer prophylaxis) varies by institution; consult local clinical guidelines.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice and therapeutic protocols vary. Always verify current prescribing information, package inserts, and institution-specific clinical guidelines before prescribing or administering medication.
